Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO)
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1742-2094
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO) ; volume:13 ; number:1 ; day:8 ; month:7 ; year:2016 ; pages:1-8 ; date:12.2016
Journal of neuroinflammation ; 13, Heft 1 (8.7.2016), 1-8, 12.2016
- Creator
-
Vaknin-Dembinsky, Adi
- Contributor
-
Charbit, Hanna
Brill, Livnat
Abramsky, Oded
Gur-Wahnon, Devorah
Ben-Dov, Iddo Z.
Lavon, Iris
SpringerLink (Online service)
- DOI
-
10.1186/s12974-016-0648-x
- URN
-
urn:nbn:de:1111-2016071128499
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Vaknin-Dembinsky, Adi
- Charbit, Hanna
- Brill, Livnat
- Abramsky, Oded
- Gur-Wahnon, Devorah
- Ben-Dov, Iddo Z.
- Lavon, Iris
- SpringerLink (Online service)
Other Objects (12)
Effectiveness of rituximab in neuromyelitis optica: a meta-analysis
Neuromyelitis optica
Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report
Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder
The history of neuromyelitis optica
The history of neuromyelitis optica
Schwannzell-Remyelinisierung bei Neuromyelitis optica
Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and Mycophenolate
Use of rituximab and risk of re-hospitalization for children with neuromyelitis optica spectrum disorder
Ergebnisse der Cortisonbehandlung bei Neuromyelitis optica
The Gut Microbiome in Neuromyelitis Optica
Effectiveness of rituximab in neuromyelitis optica: a meta-analysis
Neuromyelitis optica
Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report
Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder
The history of neuromyelitis optica
The history of neuromyelitis optica
Schwannzell-Remyelinisierung bei Neuromyelitis optica
Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and Mycophenolate
Use of rituximab and risk of re-hospitalization for children with neuromyelitis optica spectrum disorder
Ergebnisse der Cortisonbehandlung bei Neuromyelitis optica
The Gut Microbiome in Neuromyelitis Optica
Effectiveness of rituximab in neuromyelitis optica: a meta-analysis
Neuromyelitis optica
Secondary Hypogammaglobulinemia After Rituximab for Neuromyelitis Optica: A Case Report
Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder
The history of neuromyelitis optica
The history of neuromyelitis optica
Schwannzell-Remyelinisierung bei Neuromyelitis optica
Effective Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorders Compared with Azathioprine and Mycophenolate
Use of rituximab and risk of re-hospitalization for children with neuromyelitis optica spectrum disorder
Ergebnisse der Cortisonbehandlung bei Neuromyelitis optica